Definition
Patentable describes an invention, discovery, or other subject matter that meets the legal requirements for protection by a patent — meaning the law recognizes it as the kind of thing that can be patented and that the particular item satisfies the statutory conditions for patent issuance.
Modern U.S. patent law (35 U.S.C. §§ 101–103) structures patentability around four overlapping requirements:
(1) Subject matter eligibility — the invention must fall within a category the patent system protects: processes, machines, manufactures, or compositions of matter. Abstract ideas, laws of nature, and natural phenomena are categorically excluded.
(2) Novelty — the invention must not have been previously known or used in a way that places it in the prior art.
(3) Non-obviousness — the invention must not be an obvious variation of what already exists, as judged from the perspective of a person having ordinary skill in the relevant field at the time of filing.
(4) Utility — the invention must have a specific, substantial, and credible use.
An invention that satisfies all four requirements is patentable. Failure on any single requirement defeats patent protection, regardless of how the other requirements are met.
---
Common Language
Modern common usage (Wiktionary): Able to be protected by a patent; for which a patent can be granted.
Historical common usage (Webster's 1913): Suitable to be patented; capable of being patented.
The common usage is not wrong, but it is incomplete in a way that matters. In ordinary speech, calling something "patentable" often means only that it seems original or clever enough to deserve protection. In law, patentability is a formal conclusion reached only after applying a structured multi-factor analysis. A genuinely novel and useful invention can still be unpatentable — because it covers an abstract idea, because it is obvious over prior art, or because it lacks adequate disclosure. The gap between the intuitive sense ("this seems inventive") and the legal standard ("this satisfies §§ 101, 102, 103, and 112") is where patent disputes are won and lost.
---
Core Elements
The four requirements for patentability interact and have independent histories:
Subject Matter Eligibility (§ 101): The threshold question of whether the type of invention is even within patent law's scope. This has been the most turbulent area of patent doctrine since the early 2010s, with judicial exceptions for abstract ideas, laws of nature, and natural phenomena significantly narrowing what qualifies, particularly for software and biotech claims.
Novelty (§ 102): An absolute bar. Prior art that anticipates an invention — regardless of whether the inventor knew of it — destroys novelty. The definition of prior art has changed substantially between the pre-2013 first-to-invent system and the post-America Invents Act first-inventor-to-file system.
Non-Obviousness (§ 103): A relative standard. An invention may be new but still fail if the differences between it and the prior art would have been obvious to a skilled practitioner. This replaced the older "invention" requirement and remains highly fact-intensive.
Utility (§ 101): Generally easy to satisfy for mechanical and chemical inventions; more demanding for pharmaceutical compounds where specific, demonstrated utility is required.
---
Why It Matters in Research
Patentability is not a single legal concept but a composite determination, and each component has its own doctrinal trajectory. Researchers working in historical sources must be alert to several layered changes.
First, the vocabulary shifted. Nineteenth and early twentieth century courts and commentators spoke of "patentable invention" as a unitary concept, roughly blending what modern law treats as separate § 101 eligibility and § 103 non-obviousness inquiries. Black's historical definition — "suitable to be patented; entitled by law to be protected" — reflects this undifferentiated usage. The formal separation of subject matter eligibility from obviousness is a product of the 1952 Patent Act and its subsequent interpretation.
Second, the subject matter eligibility question has been dramatically reshaped by judicial doctrine since 2010. Sources predating Alice Corp. v. CLS Bank International (2014) and Mayo Collaborative Services v. Prometheus Laboratories (2012) will treat software, diagnostic method, and business method patents as far more readily patentable than current doctrine allows. This is a significant trap in secondary literature: treatises and encyclopedia entries written before this period may describe the patentable subject matter landscape in ways that are now materially inaccurate.
Third, the novelty standard changed with the Leahy-Smith America Invents Act (AIA), effective March 16, 2013. Pre-AIA and post-AIA patent applications are evaluated under different novelty rules, and the prior art universe is defined differently. Research involving patent prosecution or validity disputes must establish which regime applies to the application at issue.
Fourth, pharmaceutical patentability has its own specialized overlay, particularly under the Hatch-Waxman Act framework, where patentability intersects with regulatory exclusivity, patent listing requirements, and paragraph IV certifications. See ip_32 for that context.
When consulting Black's Law Dictionary's second edition citation to Providence Rubber Co. v. Goodyear, note that the court was working within a pre-1952 doctrinal framework in which "patentable novelty" and subject matter questions were not as sharply distinguished as they are today.
---
Historical Dictionary Support
Both editions of Black's Law Dictionary offer the same functional definition: "suitable to be patented; entitled by law to be protected by the issuance of a patent." This is accurate as far as it goes, but the definition is descriptive rather than analytic. It does not specify what makes something legally "suitable" or what "entitled by law" requires — it essentially translates the term without defining it.
The second edition's case citations are useful as a historical window. Henth Cycle Co. v. Hay, Maier v. Bloom, Boyd v. Cherry, and Providence Rubber Co. v. Goodyear all arise from an era when patentability doctrine centered heavily on whether an invention demonstrated sufficient "invention" — a concept roughly analogous to today's non-obviousness requirement, though with meaningful differences in application and emphasis.
What these historical sources miss entirely is the modern § 101 subject matter eligibility framework as interpreted by the Supreme Court's two-step Alice/Mayo test, the AIA's restructuring of novelty and prior art, and the specialized patentability frameworks developed for biotechnology following Diamond v. Chakrabarty and its progeny. Researchers should treat Black's historical definitions as useful starting points for pre-1952 research but insufficient guides to modern patentability analysis.
---
Jurisdictional Note
Patent law in the United States is federal and governed by Title 35 of the U.S. Code, with exclusive appellate jurisdiction in the Court of Appeals for the Federal Circuit. There is no meaningful state-law variation in patentability analysis. International patentability standards differ — particularly in European patent law, which applies an explicit industrial applicability requirement and treats subject matter exclusions differently — and researchers working across jurisdictions should not assume that U.S. patentability conclusions translate directly to PCT or EPO proceedings.
---
Encyclopedia Cross-Reference
ip_5: Patent Law — Overview, History, and the Patent Act (35 USC) — primary reference for patentability requirements, statutory framework, and doctrinal history.
ip_32: The Hatch-Waxman Act and Pharmaceutical Patent Litigation — relevant when patentability issues arise in the pharmaceutical context, including the intersection of patent term, regulatory exclusivity, and validity challenges.
---